metformin has been researched along with Myelodysplastic Syndromes in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brailovski, E | 1 |
| Li, Q | 1 |
| Liu, N | 1 |
| Leber, B | 1 |
| Khalaf, D | 1 |
| Sabloff, M | 1 |
| Christou, G | 1 |
| Yee, K | 1 |
| Chodirker, L | 1 |
| Parmentier, A | 1 |
| Siddiqui, M | 1 |
| Mamedov, A | 1 |
| Zhang, L | 1 |
| Liu, Y | 1 |
| Earle, CC | 1 |
| Cheung, MC | 1 |
| Mittmann, N | 1 |
| Buckstein, RJ | 1 |
| Mozessohn, L | 1 |
1 other study available for metformin and Myelodysplastic Syndromes
| Article | Year |
|---|---|
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydroxymethylglutaryl-CoA Red | 2022 |